New Zealand markets open in 7 hours 15 minutes
  • NZX 50

    11,967.72
    -66.45 (-0.55%)
     
  • NZD/USD

    0.6449
    -0.0020 (-0.31%)
     
  • ALL ORDS

    7,686.10
    -14.30 (-0.19%)
     
  • OIL

    77.37
    -0.53 (-0.68%)
     
  • GOLD

    1,929.80
    -9.40 (-0.48%)
     

Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit

REDWOOD CITY, Calif. & BOSTON, November 30, 2022--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the virtual JMP Securities Hematology and Oncology Summit being held from December 6-7, 2022.

Details of the event are as follows:

Date: Tuesday, December 6, 2022
Time: 9:40 a.m. ET

The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs) and adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005976/en/

Contacts

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com